US2017342150A1PendingUtilityA1

Method of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

59
Assignee: ABBVIE BIOTHERAPEUTICS INCPriority: Aug 7, 2006Filed: Aug 7, 2017Published: Nov 30, 2017
Est. expiryAug 7, 2026(~0.1 yrs left)· nominal 20-yr term from priority
Inventors:Daniel Afar
A61P 35/02A61P 35/00C07K 2317/732A61K 31/69A61K 39/39558C07K 2317/24A61K 45/06A61K 9/0019C07K 16/2806C07K 2317/56A61K 31/454A61K 31/573A61K 2039/542A61K 2039/505A61K 38/05C07K 16/3061A61K 39/3955A61K 39/395A61K 38/55A61K 31/4545
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods for treating MM are provided herein.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A pharmaceutical composition suitable for treating multiple myeloma in a subject, comprising a therapeutically effective amount of HuLuc63, a therapeutically effective amount of lenalidomide and/or bortezomib, and a pharmaceutically acceptable carrier, wherein said composition is capable of being administered in a single or multiple dose regimen. 
     
     
         2 . The pharmaceutical composition according to  claim 1  comprising a therapeutically effective amount of lenalidomide. 
     
     
         3 . The pharmaceutical composition according to  claim 1  comprising a therapeutically effective amount of bortezomib. 
     
     
         4 . The pharmaceutical composition according to  claim 1  comprising a therapeutically effective amount of lenalidomide and a therapeutically effective amount of bortezomib. 
     
     
         5 . The pharmaceutical composition according to  claim 1 , further comprising a therapeutically effective amount of dexamethasone. 
     
     
         6 . The pharmaceutical composition according to  claim 1 , further comprising a therapeutically effective amount of thalidomide. 
     
     
         7 . The pharmaceutical composition according to  claim 6 , further comprising a therapeutically effective amount of dexamethasone. 
     
     
         8 . The pharmaceutical composition according to  claim 1 , further comprising a therapeutically effective amount of melphalan. 
     
     
         9 . The pharmaceutical composition according to  claim 8 , further comprising a therapeutically effective amount of prednisone. 
     
     
         10 . The pharmaceutical composition according to  claim 1 , further comprising a therapeutically effective amount of doxorubicin. 
     
     
         11 . The pharmaceutical composition according to  claim 1  in which HuLuc63 is in an injectable form. 
     
     
         12 . The pharmaceutical composition according to  claim 1 , containing from 0.5 mg/kg to 20 mg/kg of HuLuc63. 
     
     
         13 . The pharmaceutical composition according to  claim 1 , containing from 1 mg/day to 50 mg/day of lenalidomide. 
     
     
         14 . The pharmaceutical composition according to  claim 1 , containing from 0.2 mg/m 2  to 2.0 mg/m 2  of bortezomib. 
     
     
         15 . The pharmaceutical composition according to  claim 1 , in which HuLuc63 is administered after the administration of lenalidomide and/or bortezomib. 
     
     
         16 . The pharmaceutical composition according to  claim 1 , in which HuLuc63 is administered concurrently with the administration of lenalidomide and/or bortezomib. 
     
     
         17 . The pharmaceutical composition according to  claim 1 , in which HuLuc63 is administered prior to the administration of lenalidomide and/or bortezomib. 
     
     
         18 . The pharmaceutical composition according to  claim 1 , in which administration of said pharmaceutical composition elicits a complete response. 
     
     
         19 . The pharmaceutical composition according to  claim 1 , in which administration of said pharmaceutical composition elicits a very good partial response. 
     
     
         20 . The pharmaceutical composition according to  claim 1 , in which administration of said pharmaceutical composition elicits a partial response. 
     
     
         21 . The pharmaceutical composition according to  claim 1 , in which administration of said pharmaceutical composition elicits a minimal response. 
     
     
         22 . A method for increasing sensitivity of a multiple myeloma cell to a therapeutic agent, comprising contacting the cell with a therapeutically effective amount of HuLuc63. 
     
     
         23 . The method according to  claim 22 , further comprising contacting the cell with a therapeutically effective amount of lenalidomide and/or bortezomib. 
     
     
         24 . The method according to  claim 22 , wherein the multiple myeloma cell is resistant to a therapeutic agent. 
     
     
         25 . The method according to  claim 24 , further comprising contacting said resistant cell with a therapeutic agent that the cell is sensitive to, said agent selected from the group consisting of thalidomide, dexamethasone, doxorubicin, melphalan, vincristine, carmustine, cyclophosphamide, prednisone, and/or combinations thereof. 
     
     
         26 . A method of treating multiple myeloma in a subject, comprising administering a therapeutically effective amount of HuLuc63, a therapeutically effective amount of lenalidomide and/or bortezomib, and a pharmaceutically acceptable carrier, wherein said composition is capable of being administered in a single or multiple dose regimen. 
     
     
         27 . The method according to  claim 26  comprising a therapeutically effective amount of lenalidomide. 
     
     
         28 . The method according to  claim 26  comprising a therapeutically effective amount of bortezomib. 
     
     
         29 . The method according to  claim 26  comprising a therapeutically effective amount of lenalidomide and a therapeutically effective amount of bortezomib. 
     
     
         30 . The method according to  claim 26 , further comprising a therapeutically effective amount of dexamethasone. 
     
     
         31 . The pharmaceutical composition according to  claim 26 , further comprising a therapeutically effective amount of thalidomide. 
     
     
         32 . The pharmaceutical composition according to  claim 31 , further comprising a therapeutically effective amount of dexamethasone. 
     
     
         33 . The pharmaceutical composition according to  claim 26 , further comprising a therapeutically effective amount of melphalan. 
     
     
         34 . The pharmaceutical composition according to  claim 33 , further comprising a therapeutically effective amount of prednisone. 
     
     
         35 . The pharmaceutical composition according to  claim 26 , further comprising a therapeutically effective amount of doxorubicin. 
     
     
         36 . The method according to  claim 26 , in which HuLuc63 is administered intravenously at a dosage from approximately 0.5 mg/kg to approximately 20 mg/kg. 
     
     
         37 . The method according to  claim 26 , in which lenalidomide is administered orally at a dosage from approximately 1 mg/day to 50 mg/day. 
     
     
         38 . The method according to  claim 26 , in which bortezomib is administered intravenously at a dosage from approximately 0.2 mg/m 2  to 2.0 mg/m 2 . 
     
     
         39 . The method according to  claim 26 , in which said treatment elicits a complete response. 
     
     
         40 . The method according to  claim 26 , in which said treatment elicits a very good partial response. 
     
     
         41 . The method according to  claim 26 , in which said treatment elicits a partial response. 
     
     
         42 . The method according to  claim 26 , in which said treatment elicits a minimal response. 
     
     
         43 . A method of treating multiple myeloma in a subject, comprising administering a pharmaceutical composition comprising a combination of a therapeutically effect amount of HuLuc63 and a therapeutically effective amount of lenalidomide and/or bortezomib. 
     
     
         44 . The method according to  claim 57  comprising a therapeutically effective amount of lenalidomide. 
     
     
         45 . The method according to  claim 57  comprising a therapeutically effective amount of bortezomib. 
     
     
         46 . The method according to  claim 57  comprising a therapeutically effective amount of lenalidomide and a therapeutically effective amount of bortezomib. 
     
     
         47 . The method according to  claim 43 , further comprising a therapeutically effective amount of dexamethasone. 
     
     
         48 . The pharmaceutical composition according to  claim 43 , further comprising a therapeutically effective amount of thalidomide. 
     
     
         49 . The pharmaceutical composition according to  claim 48 , further comprising a therapeutically effective amount of dexamethasone. 
     
     
         50 . The pharmaceutical composition according to  claim 43 , further comprising a therapeutically effective amount of melphalan. 
     
     
         51 . The pharmaceutical composition according to  claim 50 , further comprising a therapeutically effective amount of prednisone. 
     
     
         52 . The pharmaceutical composition according to  claim 43 , further comprising a therapeutically effective amount of doxorubicin. 
     
     
         53 . The method according to  claim 43 , further comprising a pharmaceutically acceptable carrier. 
     
     
         54 . The method according to  claim 43 , in which HuLuc63 is administered intravenously at a dosage from approximately 0.5 mg/kg to approximately 20 mg/kg. 
     
     
         55 . The method according to  claim 43 , in which lenalidomide is administered orally at a dosage from approximately 1 mg/day to 50 mg/day. 
     
     
         56 . The method according to  claim 43 , in which bortezomib is administered intravenously at a dosage from approximately 0.2 mg/m 2  to 2.0 mg/m 2 . 
     
     
         57 . The method according to  claim 43 , in which HuLuc63 is administered after the administration of lenalidomide or bortezomib. 
     
     
         58 . The method according to  claim 43 , in which HuLuc63 is administered concurrently with the administration of lenalidomide or bortezomib. 
     
     
         59 . The method according to  claim 43 , in which HuLuc63 is administered prior to the administration of lenalidomide or bortezomib. 
     
     
         60 . The method according to  claim 43 , in which the treatment elicits a complete response. 
     
     
         61 . The method according to  claim 43 , in which the treatment elicits a very good partial response. 
     
     
         62 . The method according to  claim 43 , in which the treatment elicits a partial response. 
     
     
         63 . The method according to  claim 43 , in which the treatment elicits a minimal response.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.